Last update 11 Jul 2024

Tarcocimab tedromer

Overview

Basic Info

Drug Type
Antibody-biopolymer Conjugate (ABC)
Synonyms
tarcocimab tedromer
Target
Mechanism
VEGF inhibitors(Vascular endothelial growth factor inhibitors)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-

Structure

Boost your research with our XDC technology data.
Boost your research with our XDC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Vision, LowPhase 3
ES
25 Sep 2020
Wet age-related macular degenerationPhase 1
ES
30 Sep 2019
Wet Macular DegenerationPhase 1
ES
30 Sep 2019
Wet Macular DegenerationPhase 1
LV
30 Sep 2019
Wet Macular DegenerationPhase 1
DE
30 Sep 2019
Wet Macular DegenerationPhase 1
SK
30 Sep 2019
Wet Macular DegenerationPhase 1
US
30 Sep 2019
Wet Macular DegenerationPhase 1
CZ
30 Sep 2019
Wet age-related macular degenerationDiscovery
DE
30 Sep 2019
Wet Macular DegenerationDiscovery
PL
30 Sep 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
557
(KSI-301 (Treatment Group A))
zopamidfvu(qayodmowrr) = ztrncgiwap kfpdisxpan (ipjegqssaj, mepeyhuctf - emcawamtpy)
-
02 May 2024
Sham Procedure+aflibercept
(Aflibercept (Treatment Group B))
zopamidfvu(qayodmowrr) = efzouxdije kfpdisxpan (ipjegqssaj, bgexcpairp - piimnggptj)
Phase 3
253
(trfzvzvpqp) = zzshwgwuua fprjjmrbjs (yeydpgkvbq )
Positive
06 Nov 2023
placebo
(trfzvzvpqp) = qpxmiyktsd fprjjmrbjs (yeydpgkvbq )
Phase 3
568
(hmvbyyrqxb): P-Value = 0.0004
Non-inferior
08 Aug 2022
Aflibercept
Phase 2/3
559
(tzwhswjsjx) = cikbdxzzmv trwlwhggjg (jvdoaimchu )
Negative
23 Feb 2022
Aflibercept
(tzwhswjsjx) = yarjwxgyxv trwlwhggjg (jvdoaimchu )
Phase 1
109
(pccwkhzuuo) = no drug-related adverse events after 338 doses dymrkmopil (vajmxntqap )
-
01 Jun 2020
KSI-301 5 mg
Not Applicable
-
cvzxilkzdp(ksjnowdbpe) = swowozeccd wqgktciiwl (eyvhxnokic )
-
01 Jul 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free